Cooper Companies, Inc. (The) (NYSE:COO) – Equities researchers at Northcoast Research boosted their Q3 2017 earnings per share estimates for Cooper Companies, Inc. (The) in a research note issued on Monday. Northcoast Research analyst D. Keiser now forecasts that the medical device company will post earnings of $2.64 per share for the quarter, up from their prior forecast of $2.59. Northcoast Research also issued estimates for Cooper Companies, Inc. (The)’s Q4 2017 earnings at $2.66 EPS, FY2017 earnings at $9.73 EPS, Q1 2018 earnings at $2.37 EPS, Q2 2018 earnings at $2.78 EPS, Q3 2018 earnings at $2.88 EPS, Q4 2018 earnings at $2.85 EPS and FY2018 earnings at $10.88 EPS.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, June 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $250.00 target price (up from $220.00) on shares of Cooper Companies, Inc. (The) in a research note on Saturday, June 3rd. Stifel Nicolaus increased their target price on shares of Cooper Companies, Inc. (The) from $220.00 to $231.00 and gave the stock a “buy” rating in a research note on Friday, June 2nd. BMO Capital Markets reiterated a “buy” rating and issued a $255.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Thursday, July 13th. Finally, Oppenheimer Holdings, Inc. set a $225.00 target price on shares of Cooper Companies, Inc. (The) and gave the stock a “hold” rating in a research note on Saturday, June 3rd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $237.00.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/18/brokers-issue-forecasts-for-cooper-companies-inc-thes-q3-2017-earnings-coo.html.

Cooper Companies, Inc. (NYSE COO) opened at 251.98 on Tuesday. The firm has a market capitalization of $12.31 billion, a P/E ratio of 37.78 and a beta of 0.61. Cooper Companies, Inc. has a 12 month low of $158.73 and a 12 month high of $252.85. The firm’s 50-day moving average is $229.73 and its 200 day moving average is $200.61.

Cooper Companies, Inc. (The) (NYSE:COO) last announced its quarterly earnings data on Thursday, June 1st. The medical device company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.25 by $0.25. Cooper Companies, Inc. (The) had a net margin of 16.02% and a return on equity of 15.88%. The business had revenue of $522.40 million during the quarter, compared to the consensus estimate of $520.71 million. During the same period in the previous year, the business earned $2.05 earnings per share. The company’s revenue was up 8.0% on a year-over-year basis.

The business also recently disclosed a semiannual dividend, which will be paid on Monday, August 7th. Stockholders of record on Friday, July 21st will be given a dividend of $0.03 per share. This represents a dividend yield of 0.02%. The ex-dividend date of this dividend is Wednesday, July 19th. Cooper Companies, Inc. (The)’s dividend payout ratio (DPR) is currently 0.90%.

Cooper Companies, Inc. (The) announced that its board has authorized a stock buyback plan on Tuesday, March 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 5.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

In other news, Director Stanley Md Zinberg sold 816 shares of the firm’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $243.14, for a total transaction of $198,402.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Carol R. Kaufman sold 44,092 shares of the firm’s stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $242.81, for a total transaction of $10,705,978.52. Following the sale, the executive vice president now owns 60,419 shares in the company, valued at approximately $14,670,337.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,331 shares of company stock worth $16,400,454. Corporate insiders own 1.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Creative Planning boosted its stake in Cooper Companies, Inc. (The) by 0.8% in the second quarter. Creative Planning now owns 1,909 shares of the medical device company’s stock valued at $457,000 after buying an additional 16 shares during the period. Genesee Valley Trust Co. boosted its stake in Cooper Companies, Inc. (The) by 1.1% in the first quarter. Genesee Valley Trust Co. now owns 1,957 shares of the medical device company’s stock valued at $391,000 after buying an additional 21 shares during the period. Pacer Advisors Inc. boosted its stake in Cooper Companies, Inc. (The) by 3.8% in the first quarter. Pacer Advisors Inc. now owns 848 shares of the medical device company’s stock valued at $170,000 after buying an additional 31 shares during the period. Glen Harbor Capital Management LLC boosted its stake in Cooper Companies, Inc. (The) by 2.4% in the first quarter. Glen Harbor Capital Management LLC now owns 1,344 shares of the medical device company’s stock valued at $269,000 after buying an additional 32 shares during the period. Finally, First Bank & Trust boosted its stake in Cooper Companies, Inc. (The) by 3.6% in the first quarter. First Bank & Trust now owns 1,056 shares of the medical device company’s stock valued at $211,000 after buying an additional 37 shares during the period. Hedge funds and other institutional investors own 98.09% of the company’s stock.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Earnings History and Estimates for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.